Salbutamol + Ipratropium: Uses, Dosage, Side Effects | MedexInfo
Salbutamol + Ipratropium
Rx
Generic NameSalbutamol + Ipratropium
Therapeutic ClassCombined Bronchodilator (SABA + SAMA)
Common StrengthSalbutamol 100 µg + Ipratropium 20 µg per inhalation (MDI), Salbutamol 2.5 mg + Ipratropium 0.5 mg per nebulizer solution
Max / 24hAs prescribed; adjust based on age and severity
PregnancyGenerally considered safe if clearly needed
Indications ▼
Acute bronchospasm in asthma
Exacerbations of COPD
Patients needing combined bronchodilator therapy for rapid relief
Mechanism & Pharmacokinetics ▼
Mechanism: Salbutamol is a selective β2-agonist causing bronchodilation by relaxing bronchial smooth muscle. Ipratropium is an anticholinergic agent that blocks muscarinic receptors, reducing bronchoconstriction and mucus secretion. Combined use provides synergistic bronchodilation.
Pharmacokinetics: Inhaled salbutamol has rapid onset (5–15 min), metabolized in liver, excreted mainly in urine. Ipratropium onset 15–30 min, peak effect 1–2 hours, minimal systemic absorption; mainly excreted unchanged in urine.
Dosage & Administration ▼
| Formulation | Dose | Frequency |
|---|---|---|
| MDI | 2 inhalations (100 µg + 20 µg each) | Every 4–6 hours as needed |
| Nebulizer solution | 2.5 mg Salbutamol + 0.5 mg Ipratropium in 2–5 mL saline | Every 4–6 hours as needed |
Note: Use inhalation route for rapid relief. Adjust dose based on age, response, and severity.
Side Effects ▼
Tremor, nervousness
Palpitations, tachycardia
Headache, dizziness
Dry mouth, cough
Rare: arrhythmia, urinary retention
Contraindications ▼
Hypersensitivity to salbutamol, ipratropium, or components
Severe cardiovascular disorders (use with caution)
Urinary retention (relative caution with ipratropium)
Drug Interaction ▼
Non-selective β-blockers: may reduce bronchodilator effect
MAO inhibitors or tricyclic antidepressants: may enhance cardiovascular effects
Other anticholinergics: additive effects
Pregnancy & Lactation ▼
Use only if clearly needed; generally considered safe in pregnancy
Excreted in breast milk; monitor infant if used during lactation
Clinical / Research Summary ▼
Clinical Role: Combined bronchodilator for rapid relief of bronchospasm in asthma and COPD, particularly in exacerbations.
Advantage: Synergistic effect provides superior bronchodilation compared to either agent alone.
Limitation: Does not control underlying inflammation; frequent use requires controller therapy adjustment.
Monitoring: Symptom relief, heart rate, urinary retention in high-risk patients.
Patient Counseling Points ▼
Use as directed, preferably via inhaler or nebulizer
Do not exceed prescribed dose
Report palpitations, chest pain, urinary difficulty, or excessive tremor
Keep rescue inhaler accessible at all times
Storage & Handling ▼
Store below 30°C
Protect from moisture and light
Keep out of reach of children
Brand Names (Bangladesh & Global) ▼
Salpium® Nebuliser Solution
Medical Disclaimer: For educational purposes only. Not a substitute for professional medical advice.
Reference Hubs:
.png)
